Switching scleroderma

While existing treatment options for localized scleroderma target inflammation, Fibrocell Science Inc. (NASDAQ:FCSC) and partner Intrexon Corp. (NYSE:XON) plan to enter the clinic next half with FCX-013, a therapy that could reverse fibrosis in patients with moderate to severe disease.

Localized scleroderma is characterized by excess collagen production that leads to fibrosis of the skin, which could extend to the underlying tissue and muscle. Moderate to severe forms of the disease can lead to pain and restricted motion and impair growth of the affected limbs in children. ...